University of Notre Dame DU Lac raised its holdings in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 9.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,989 shares of the biopharmaceutical company’s stock after buying an additional 3,460 shares during the period. University of Notre Dame DU Lac owned about 0.08% of Clovis Oncology worth $2,719,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. Amalgamated Bank boosted its position in shares of Clovis Oncology by 16.1% during the third quarter. Amalgamated Bank now owns 5,587 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 776 shares during the period. Greenwood Capital Associates LLC boosted its position in shares of Clovis Oncology by 21.6% during the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 996 shares during the period. Geode Capital Management LLC boosted its position in shares of Clovis Oncology by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 436,518 shares of the biopharmaceutical company’s stock valued at $29,683,000 after buying an additional 1,206 shares during the period. Capital Analysts LLC purchased a new position in shares of Clovis Oncology during the third quarter valued at approximately $111,000. Finally, Sheaff Brock Investment Advisors LLC boosted its position in shares of Clovis Oncology by 30.1% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 6,376 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 1,476 shares during the period.
Several brokerages have issued reports on CLVS. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Leerink Swann restated an “outperform” rating and set a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. Oppenheimer reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Thursday, January 11th. Finally, BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $87.84.
Shares of Clovis Oncology Inc (CLVS) traded down $2.49 during trading hours on Wednesday, reaching $59.51. 589,050 shares of the company were exchanged, compared to its average volume of 1,318,673. The company has a market capitalization of $3,152.73, a P/E ratio of -8.03 and a beta of 1.10. Clovis Oncology Inc has a 52 week low of $45.42 and a 52 week high of $99.45. The company has a quick ratio of 7.35, a current ratio of 7.69 and a debt-to-equity ratio of 0.77.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.25. The company had revenue of $17.04 million during the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. Clovis Oncology’s revenue for the quarter was up 21746.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.83) earnings per share. equities analysts anticipate that Clovis Oncology Inc will post -4.75 earnings per share for the current fiscal year.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $64.16, for a total transaction of $192,480.00. Following the transaction, the insider now directly owns 182,583 shares of the company’s stock, valued at $11,714,525.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $64.97, for a total value of $292,365.00. Following the transaction, the director now directly owns 21,118 shares in the company, valued at $1,372,036.46. The disclosure for this sale can be found here. Insiders sold 22,500 shares of company stock valued at $1,371,210 in the last three months. 12.50% of the stock is currently owned by insiders.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.